Residency Listing

Stanford Health Care
300 Pasteur Drive
Stanford, CA 94305
Code: 92011
NMS Code: 621060
Postgraduate Year Two (PGY2)
Oncology Pharmacy
Accreditation Status: Accredited
Residency Program Director: Eun Kim, PharmD, MS, BCOP, BCPS
(650) 725-5299
Fax: (650) 736-8781
Director of Pharmacy: Deepak R. Sisodiya, Pharm.D., MHA, BCPS
Fax: 650-725-4693
Program Contact: Mark J. Klanjac, Pharm.D., BCPS
(650) 724-3449
Fax: (650) 725-4693
Residency Information:
Duration/Type: 12 mo. residency
Number of Positions: 1
Application Deadline: 2018-12-31
Starting Date: 2019-07-15
Estimated Stipend: 80000
Interview Required: Yes
Residency Special Features:   As a PGY2 hematology/oncology specialty resident, you will gain competence in the field of hematology/oncology pharmacy through a variety of integrated practice experiences in both inpatient and outpatient settings. In addition to clinical services, you will serve as preceptor to PGY1 residents and pharmacy students. Rotations will include inpatient oncology and hematology, BMT, outpatient oncology and hematology, and a variety of elective rotations.
Fringe Benefits:   Your expertise will be rewarded with an estimated stipend of $83,000 and benefits such as paid time off for illness or vacation (10 days), health insurance (family coverage available) and paid travel expenses to professional meetings.
Special Requirements for Acceptance:   Candidates must have a Pharm.D. degree and a California intern license must be obtained before the first day of residency.
Training Site Type: Hospital
Owner Affiliate: Stanford Hospitals and Clinics
Model Type(s): Teaching
Tax Status: Nonprofit
Professional Staff: 90
Non-Professional Staff: 60
Total Beds: 613
Average Daily Census: 400
Site Special Features:   If you have a special interest in the practice of hematology/oncology pharmacy, and hope to achieve board certification in the specialty, you will find a great educational opportunity at Stanford. You will be supported by a devoted staff who share your passion for the specialty and practice state of the art, cutting edge hematology/oncology medicine.